This property of LM22A-4 was described in the original paper (Massa et al., 2010) and in all subsequent reports using different experimental mouse models with reduced BDNF levels, including models of Huntington's disease (Simmons et al., 2013), traumatic brain injury-induced epilepsy (Gu et al., 2018), Dravet's disease (Gu et al., 2022), compulsive alcohol drinking (Warnault et al., 2016), non-arteritic anterior ischemic optic neuropathy (Ali Shariati et al., 2018) and chemotherapy-induced cognitive decline (Geraghty et al., 2019). This evidence concerns the gene BDNF and Huntington disease.